Table 5 Preclinical studies of targeting other molecular chaperones
From: Advances in the structures, mechanisms and targeting of molecular chaperones
Compound | Structure | Activity | Mechanism (Sites) |
|---|---|---|---|
Compound 2H |
| cIC50 = 5.0 µM | HSP110 Inhibitor (/) |
iHSP110-33 |
| bIC50 = 58 μM | HSP110 Inhibitor (NBD) |
GdnHCl |
| Kd ≈ 600 μM | ClpB Inhibitor (NTD) |
DBeQ |
| aIC50 ≈ 5.0 μM | ClpB Inhibitor (NTD) |
Mizoribine |
| / | HSP60 inhibitor (NBD) |
ETB |
| cIC50 = 1.1 μM | HSP60 inhibitor (Cys442 covalent site) |
MC |
| / | HSP60 inhibitor (/) |
O-carboranyl-phenoxyacetanilide |
| cIC50 = 0.74 μM | HSP60 inhibitor (NBD) |
[Au(TPP)Cl] |
| cIC50 = 1.1 μM | HSP60 inhibitor (/) |
KHS101 |
| cIC50 = 14 μM | HSP60 inhibitor (/) |
RP101 |
| / | HSP27 inhibitor (Phe29 and Phe33) |
J2 |
| cIC50 = 99 μM | HSP27 inhibitor (Cysteine-thiol group) |
MK-933 |
| / | HSP27 inhibitor (NTD) |
